Expense Ratio
The annual fee the ETF charges, deducted daily from NAV. A 0.05% ratio costs you $5/year per $10,000 invested, over 30 years that's the difference between a great fund and a mediocre one.
Learn more →State Street® SPDR® S&P® Pharmaceuticals ETF
XPHState Street (SPDR)Equity
AI Agents
NAV
$57.84
Net Assets
$355.7M
Expense Ratio
0.35%
YTD
-3.60%
1Y
+24.05%
3Y CAGR
+10.96%
5Y CAGR
+2.75%
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
Price History1,255 daily observations
Price History▲ 41.82% over 1Y
Returns PerformanceTrailing total returns
| YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|
| -3.60% | +24.05% | +10.96% | +2.75% |
Expense Ratio
Net (after waivers)0.35%
Gross (before waivers)0.35%
Net expense ratio reflects fee waivers and reimbursements actually paid by investors. Gross is the full management cost.
Sector Allocation2 sectors
Unclassified Equity74.28%
Healthcare25.65%
Top 10 Holdings ConcentrationWhat share of the fund the largest 10 positions occupy
Top 10 Weight
23.5%
Total Holdings
59
Verdict
broadly diversified
Top Holdings59 positions
💡Reading the Holdings Table
The Weight column shows how much of the ETF's assets sit in each constituent. The Allocation bar scales each weight to the largest position so you can see relative concentration at a glance, and the Cumul. column tracks the running total, a fast read on how top-heavy this ETF is. The top 10 holdings account for 23.5% of assets. Click any constituent name to open its US stock detail page.
📖 Learn: Diversification & Asset Allocation →| # | Holding | Sector | Allocation | Weight | Cumul. |
|---|---|---|---|---|---|
| 1 | ORGANON + COOGN | Healthcare | 3.68% | 3.7% | |
| 2 | ENLIVEN THERAPEUTICS INCELVN | Unclassified Equity | 2.62% | 6.3% | |
| 3 | CORCEPT THERAPEUTICS INCCORT | Unclassified Equity | 2.45% | 8.8% | |
| 4 | OMEROS CORPOMER | Unclassified Equity | 2.21% | 11.0% | |
| 5 | TREVI THERAPEUTICS INCTRVI | Unclassified Equity | 2.14% | 13.1% | |
| 6 | NEKTAR THERAPEUTICSNKTR | Unclassified Equity | 2.12% | 15.2% | |
| 7 | AXSOME THERAPEUTICS INCAXSM | Unclassified Equity | 2.10% | 17.3% | |
| 8 | PERRIGO CO PLCPRGO | Healthcare | 2.10% | 19.4% | |
| 9 | TERNS PHARMACEUTICALS INCTERN | Unclassified Equity | 2.03% | 21.5% | |
| 10 | AMYLYX PHARMACEUTICALS INCAMLX | Unclassified Equity | 2.02% | 23.5% | |
| 11 | DEFINIUM THERAPEUTICS INCDFTX | Unclassified Equity | 2.02% | 25.5% | |
| 12 | HARROW INCHROW | Unclassified Equity | 2.01% | 27.5% | |
| 13 | PACIRA BIOSCIENCES INCPCRX | Unclassified Equity | 2.00% | 29.5% | |
| 14 | LIGAND PHARMACEUTICALSLGND | Unclassified Equity | 1.96% | 31.5% | |
| 15 | MBX BIOSCIENCES INCMBX | Unclassified Equity | 1.95% | 33.4% | |
| 16 | JAZZ PHARMACEUTICALS PLCJAZZ | Unclassified Equity | 1.94% | 35.4% | |
| 17 | HARMONY BIOSCIENCES HOLDINGSHRMY | Unclassified Equity | 1.93% | 37.3% | |
| 18 | ROYALTY PHARMA PLC CL ARPRX | Unclassified Equity | 1.90% | 39.2% | |
| 19 | VIATRIS INCVTRS | Healthcare | 1.90% | 41.1% | |
| 20 | INDIVIOR PHARMACEUTICALS INCINDV | Unclassified Equity | 1.87% | 43.0% | |
| Total (top 20) | 43.0% | ||||
Check Holdings Overlap
Sign in to see if this ETF's holdings overlap with stocks already in your portfolio. Knowing your total exposure helps avoid accidental over-concentration.
Sign In to Check OverlapInvestment CalculatorSee what investing in XPH might be worth
$
You invest
$10,000
Estimated gain
$3,117
Final value
$13,117
Projections assume returns compound at the chosen CAGR consistently for 10 years, actual returns will vary year-to-year. Past performance is not a guarantee of future results.
Key Concepts to UnderstandFive things that drive ETF performance more than anything else
Net Assets (AUM)
Total money the ETF manages. Larger AUM usually means tighter bid-ask spreads and lower closure risk. ETFs under $50M are sometimes liquidated by the issuer.
Learn more →NAV
Net Asset Value, the per-share value of everything the ETF owns minus what it owes, calculated end-of-day. The trading price can drift slightly above (premium) or below (discount) NAV during the day.
Learn more →Tracking Error
How closely the ETF's returns match its benchmark. Index ETFs aim for near-zero tracking error; high tracking error in an index fund usually signals fees, sampling, or poor management.
Learn more →Total Return
Capital gain + reinvested dividends. The headline price chart only shows the price part, total return is what you actually pocket, and is the only fair way to compare ETFs across asset classes.
Learn more →Similar ETFs
About This ETF
Provider
State Street (SPDR)
Asset Class
Equity
Inception Date
Jun 19, 2006
Top Sector
Unclassified Equity (74.3%)
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
US ETF data is for educational purposes only. Past performance does not guarantee future returns. Exchange-traded funds carry market risk and may lose value. Read the prospectus and consult a registered investment advisor before investing. Equiscale does not provide investment advice.